Edition:
United Kingdom

Onxeo SA (C4X.PA)

C4X.PA on Paris Stock Exchange

1.44EUR
4:35pm BST
Change (% chg)

€-0.06 (-4.33%)
Prev Close
€1.50
Open
€1.52
Day's High
€1.52
Day's Low
€1.43
Volume
219,453
Avg. Vol
612,073
52-wk High
€5.46
52-wk Low
€0.98

Latest Key Developments (Source: Significant Developments)

Onxeo FY Recurring Operating Loss Narrows To EUR 19.2‍​ Million
Thursday, 29 Mar 2018 

March 29 (Reuters) - ONXEO SA ::FY REVENUE EUR ‍​9.5 MILLION VERSUS EUR 4.4 MILLION YEAR AGO.FY RECURRING OPERATING LOSS EUR 19.2‍​ MILLION VERSUS LOSS OF EUR 23.2 MILLION YEAR AGO.FY NET LOSS EUR 59.1‍​ MILLION VERSUS LOSS OF EUR 22.7 MILLION YEAR AGO.END-DEC. CASH POSITION OF EUR 14.3 MILLION, COVERING CURRENT PROGRAMME UNTIL MID-2019.LAUNCH OF PRECLINICAL STUDIES WITH FIRST MOLECULE GENERATED BY PLATON EXPECTED BEFORE END-2018.RESULTS OF STUDY ON COMBINATION OF BELINOSTAT AND ASIDNA TO BE PRESENTED AT 2018 AACR CONGRESS.RESULTS OF SECOND PHASE I CLINICAL STUDY WITH ASIDNA, DRIIV, EXPECTED BEFORE YEAR-END.SAYS MIGHT BE ABLE TO LAUNCH CLINICAL TRIAL WITH BELINOSTAT AND ASIDNA COMBINATION IN 2018.  Full Article

Onxeo Says To Record Impairment Charge
Wednesday, 14 Mar 2018 

March 14 (Reuters) - Onxeo Sa ::ONXEO SA <<>> SAYS IT WILL RECORD AN IMPAIRMENT CHARGE OF ABOUT EUR 38 MILLION IN ITS 2017 CONSOLIDATED ACCOUNTS.ONXEO SA <<>> - IMPAIRMENT CHARGE PURSUANT TO VALUE TESTS PERFORMED IN ACCORDANCE WITH IFRS ACCOUNTING STANDARDS.ONXEO SA <<>> SAYS ACCOUNTING ADJUSTMENT DOES NOT IMPACT IN ANY WAY CO'S CURRENT OR FUTURE CASH BALANCE.  Full Article

Onxeo gets 10th positive DSMB recommendation to continue Livatag relive phase III trial in HCC
Tuesday, 23 May 2017 

May 23 (Reuters) - ONXEO SA :ONXEO ANNOUNCES 10TH POSITIVE DSMB RECOMMENDATION TO CONTINUE LIVATAG® RELIVE PHASE III TRIAL IN HCC.  Full Article

Onxeo SA Q3 revenues up at 1.23 mln euros
Tuesday, 25 Oct 2016 

Onxeo Sa : Revenues for Q3 of 2016 amounted to 1.23 million euros ($1.34 million) compared to 1.1 million euros in Q3 of 2015 .12.5 million euros capital increase successfully completed.  Full Article

Onxeo issues 5,434,783 new shares for 12.5 million euros
Friday, 30 Sep 2016 

Onxeo SA :Capital increase through the issue of 5,434,783 new ordinary shares for an amount of 12.5 million euros ($13.98 million).  Full Article

BRIEF-Onxeo H1 net loss narrows to 11.2 million euros (July 28)
Friday, 29 Jul 2016 

Removes reference to Livatag in headline of July 28 brief item.Onxeo SA : H1 net loss of 11.2 million euros ($12.40 million) versus loss of 11.3 million euros year ago . H1 revenue 1.8 million euros versus 1.5 million euros year ago . Livatag phase III trial in HCC: 80 pct of patients randomized . First development steps of new oral formulation of Beleodaq .19.6 million euros cash-on-hand as of June 30, 2016.  Full Article

Onxeo Livatag H1 net loss narrows to 11.2 million euros
Thursday, 28 Jul 2016 

Onxeo SA : H1 net loss of 11.2 million euros ($12.40 million) versus loss of 11.3 million euros year ago . H1 revenue 1.8 million euros versus 1.5 million euros year ago . Livatag phase III trial in HCC: 80 pct of patients randomized . First development steps of new oral formulation of Beleodaq .Eur 19.6m cash-on-hand as of June 30, 2016.  Full Article

Onxeo signs exclusive license agreement with Pint Pharma
Wednesday, 27 Jul 2016 

Onxeo SA : Signs exclusive license agreement with Pint Pharma for commercialization of Beleodaq in PTCL in South America .Onxeo to receive upfront payment, regulatory and commercial milestones, and sales royalties for a total deal value greater than USD 20 million.  Full Article